- Tytuł:
- Apalutamide as a therapeutic option in case of local failure in the nmCRPC
- Autorzy:
- Stankiewicz, Magdalena
- Powiązania:
- https://bibliotekanauki.pl/articles/22676730.pdf
- Data publikacji:
- 2023-04-01
- Wydawca:
- Medical Education
- Tematy:
-
prostate cancer
castration resistance
apalutamide - Opis:
- Apalutamide is a non-steroidal selective androgen receptor inhibitor approved for the treatment of high-risk non-metastatic castration-resistant prostate cancer and metastatic hormone-sensitive prostate cancer. The paper describes a case of a patient diagnosed with prostate cancer with a long-term course of the disease. The patient was diagnosed with a non-metastatic castration-resistant stage 18 years after primary treatment. Systemic treatment with apalutamide was recommended. Initially, the treatment was carried out as part of the extended access to apalutamide program and from March 2022 as part of the B.56 drug program. The study presents the effectiveness and safety of the therapy in a 12-month follow-up period and discusses controversial aspects of the patient's previous treatments.
- Źródło:
-
OncoReview; 2023, 13, 1; 13-19
2450-6125 - Pojawia się w:
- OncoReview
- Dostawca treści:
- Biblioteka Nauki
Artykuł